SRZN (Surrozen Corp) שולי הרווח הגולמי

Surrozen, Inc. (SRZN) is establishing a foundation in regenerative biology by utilizing antibodies for organ restoration. This gross margin chart demonstrates a peak in efficiency, where the current value equals 98.00. However, strict FDA oversight and lobbying create significant hurdles. Patent protection of the Wnt pathway and massive R&D expenditures limit the entry of new players while tests confirm safety.
פילוחים אנליטיים ודוחות נתונים של חברת Surrozen (SRZN)

An analysis of the gross margin of Surrozen, Inc. (SRZN) allows for an assessment of the efficiency of covering direct costs through operating revenue, expressed as the percentage of profit after deducting the cost of goods sold. Since the company is in the drug development stage and has no sales, this indicator reflects a current lack of pricing power and the total dependence of future profitability on FDA approval.